Lazard Upgrades Valeant Pharma (VRX) to Hold
More News related to VRX
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
- Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharmaceuticals Reports Third Quarter Financial Results
More News related to Upgrades
- Knight (KNX), USA Truck (USAK), Werner (WERN) Higher Amid Avondale Upgrades
- William Blair Upgrades Manpower (MAN) Amid Strong Jobs Report
- Pritchard Capital Upgrades Geokinetics (GOK) to Buy
- Argus Upgrades ADC Telecommunications (ADCT) to Buy
- Oppenheimer Upgrades Akamai Tech (AKAM) to Outperform
Lazard Capital upgrades Valeant Pharmaceuticals (NYSE: VRX) from Sell to Hold.
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
-0.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
